Latest Breaking News On - Jordi xaus - Page 1 : vimarsana.com

ORYZON Awarded with a Grant for ORY-4001 From the ALS Association in the U S

To explore Oryzon’s clinical candidate ORY-4001 in ALS The ALS Association to provide 500,000 USD funding MADRID, Spain and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the start of a preclinical collaboration with the ALS Association. The Association has awarded Oryzon a 498,690 USD grant through i

Comunidad autonoma de catalunaSan diegoUnited statesJordi xausPatricia cobo daniel foleyAshleyr robinsonKuldip daveLifesci advisorsIsabel barnett drug development programCharcot marie toothIsabel barnett drug developmentSpanish comisiNacional del mercado de valoresSci advisorsAls associationThe association

Oryzon Genomics S A : receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies -October 03, 2023 at 01:41 am EDT

3 October 2023 ORYZON receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies Two.

Comunidad autonoma de catalunaUnited statesSan diegoSpanish stateJordi xausMinistry of scienceCentre de regulaciSpanish state research agencySpanish ministry of scienceEuropean union nextgenerationEuropean unionUniversitat autChief scientific officerSpanish ministryAbout vafidemstatSecondary progressive

Oryzon Genomics S A : Positive preclinical data of ORY-4001 for the treatment of Charcot-Marie-Tooth (CMT) disease presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

21 June 2023 Positive preclinical data of ORY-4001 for the treatment of Charcot-Marie-Tooth disease presented at the 2023 Peripheral Nerve Society Annual Meeting . | June 21, 2023

United statesSan diegoComunidad autonoma de catalunaJordi xausPeripheral nerve societyResearch foundationNerve societyAmyotrophic lateral sclerosis

Positive Preclinical Data of ORY-4001 for the Treatment of Charcot-Marie-Tooth (CMT) Disease Presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

Positive Preclinical Data of ORY-4001 for the Treatment of Charcot-Marie-Tooth (CMT) Disease Presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoComunidad autonoma de catalunaJordi xausPeripheral nerve societyResearch foundationPreclinical dataDisease presentedNerve societyAmyotrophic lateral sclerosisSpanish comisiNacional del mercado de valores

ORYZON to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

30.05.2023 - Selected for Oral PresentationStudy done in the CMT1A mouse modelSupported by the CMT Research Foundation MADRID, Spain and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage . Seite 1

United statesJordi xausBella centerPeripheral nerve societyResearch foundationNerve societyAnnual meetingNovel potentSelective oxadiazole basedShows pre clinical therapeutic efficacyOryzon genomicss a